Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo OpGen, Inc.
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

Number of employees : 40 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Product2.4081.3%2.1762% -9.49%
Collaboration0.51617.5%1.3337.9% +156.77%
Laboratory0.0351.2%0.0050.2% -84.32%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States2.95100%3.50100% +18.75%
Managers
NameAgeSinceTitle
Oliver Schacht, Dr.492020Chief Executive Officer & Director
Bill E. Rhodes662020Non-Executive Chairman
Johannes Bacher502020Chief Operating Officer
Timothy C. Dec612015CFO, Secretary & Chief Accounting Officer
Vadim Sapiro482011Chief Information Officer
G. Terrance Walker, Dr.592013Senior Vice President-Research & Development
Faranak Atrzadeh--Chief Marketing & Scientific Affairs Officer
Evan Jones622020Director
R. Donald Elsey662019Independent Director
Mario P. Crovetto652020Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 19,714,348 19,693,871 99.9% 0 0.0% 99.9%
Shareholders
NameEquities%
Heights Capital Management, Inc. 200,000 1.01%
The Vanguard Group, Inc. 147,343 0.74%
G1 Execution Services LLC 75,256 0.38%
Millennium Management LLC 71,698 0.36%
Renaissance Technologies LLC 68,188 0.34%
Geode Capital Management LLC 56,165 0.28%
Virtu Financial BD LLC 53,300 0.27%
Citadel Advisors LLC 38,289 0.19%
Wedbush Securities, Inc. (Investment Management) 37,013 0.19%
Northern Trust Investments, Inc.(Investment Management) 34,277 0.17%
Company contact information
OpGen, Inc.
708 Quince Orchard Road
Suite 250
Gaithersburg, MD 20878

Phone : +1.301.869.9683
Fax : +1.301.869.9684
Web : http://www.opgen.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
OPGEN, INC.112.39%47
LONZA GROUP AG64.78%47 655
SEAGEN INC.73.31%34 455
IQVIA HOLDINGS INC.12.29%33 260
CELLTRION, INC.34.81%28 816
MODERNA, INC.264.57%28 138
IMMUNOMEDICS, INC.314.56%20 291
INCYTE CORPORATION2.28%19 532
ALNYLAM PHARMACEUTICALS, INC.22.69%16 404
HANGZHOU TIGERMED CONSULTING CO.,LTD88.46%15 228
PPD, INC.0.00%12 758
PHARMARON BEIJING CO., LTD.115.75%12 562
QIAGEN N.V.54.08%11 913
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.52.61%11 601
ICON PUBLIC LIMITED COMPANY18.06%10 701
BIO-TECHNE CORPORATION20.49%10 198
GALAPAGOS NV-40.05%8 641
CRISPR THERAPEUTICS AG75.19%7 487
PRA HEALTH SCIENCES, INC.-1.71%6 981
IONIS PHARMACEUTICALS, INC.-21.52%6 622
ACADIA PHARMACEUTICALS INC.-3.67%6 546